There is an urgent need to develop novel therapies for patients with highly malignant uveal melanomas in the eye. Patients with uveal melanoma die within 1-2 years of diagnosis despite current conventional therapies, including eye enucleation, brachotherapy and chemotherapy. Hypoxia drives tumor progression by activating angiogenesis, cell motility and metastasis, as well as metabolic adaptation to growth under a hypoxic environment and is a major factor in the resistance of cancer cells to radio- and chemotherapies. Hypoxia activates transcription factors of the Hypoxia-Inducible Factor (HIF) family that induce the expression of genes that encode pro-angiogenic factors and glycolytic enzymes essential for tumor growth and favor tumor invasion. Based on these findings, we formulated the central hypothesis that development of hypoxia and activation of the HIF pathway play a critical role in ocular cancer growth and spread, and that therapeutic targeting of this pathway using small molecule inhibitors will inhibit ocular tumor growth and metastasis. We have generated substantial preliminary data validating this concept. We show that our lead probe (KCN1) is a potent inhibitor of the in vivo growth of uveal melanoma in the eye (70% tumor size reduction) and its metastasis to the liver (50% reduction in number of metastases), while being extremely well tolerated. The overall goals of this proposal are to refine the structur of the novel HIF pathway inhibitor (HPI) chemical probes we developed, optimize their potency and pharmacological properties, leading to the identification of 1- 2 clinical lead probes that wil be ready to undergo IND-directed pharmacology and toxicology towards phase 1 clinical testing in patients with malignant uveal melanoma through the NCI NExT program. Our multi- disciplinary team has expertise in major aspects of chemical probe development and will divide the project tasks into the following aims: screening analogs of the parent compound in primary and secondary assays to identify and confirm chemical probes with improved potency and solubility (Aim 1);screening analogs of the optimized probes for improved pharmacology and formulation development (Aim 2);and determine the anti- tumor efficacy of the optimized lead probe(s) in orthotopic uveal melanoma models in mice (Aim 3).

Public Health Relevance

We want to further optimize the pipeline of novel anti-cancer chemical probes we have discovered, by improving their potency, activity, pharmacological properties and establishing their preclinical safety. This will accelerate their translation toward clinical trials to test their potential as novel drugs for the treatment of patients with malignant ocular tumors, and possibly other cancers. !

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-MDCN-C (58))
Program Officer
Forry, Suzanne L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
Schools of Medicine
United States
Zip Code
Osuka, Satoru; Van Meir, Erwin G (2017) Overcoming therapeutic resistance in glioblastoma: the way forward. J Clin Invest 127:415-426
Ferguson, Jalisa H; De Los Santos, Zeus; Devi, Saroja N et al. (2017) Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility. J Enzyme Inhib Med Chem 32:992-1001
Dai, Xin; Kaluz, Stefan; Jiang, Ying et al. (2017) A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis. Oncotarget 8:99245-99260
Ferguson, Jalisa; De Los Santos, Zeus; Devi, Narra et al. (2017) Examining the structure-activity relationship of benzopyran-based inhibitors of the hypoxia inducible factor-1 pathway. Bioorg Med Chem Lett 27:1731-1736
Kim, Yong Joon; Kaluz, Stefan; Mehta, Anil et al. (2017) Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example. Bio Protoc 7:
Liao, Albert; Mittal, Pardeep; Lawson, David H et al. (2017) Radiologic and Histopathologic Correlation of Different Growth Patterns of Metastatic Uveal Melanoma to the Liver. Ophthalmology :
Ji, Xingyue; Damera, Krishna; Zheng, Yueqin et al. (2016) Toward Carbon Monoxide-Based Therapeutics: Critical Drug Delivery and Developability Issues. J Pharm Sci 105:406-416
Luke, Jason J; Triozzi, Pierre L; McKenna, Kyle C et al. (2015) Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res 28:135-47